[go: up one dir, main page]

AR100021A1 - Combinaciones de ligando de receptores sigma y aine - Google Patents

Combinaciones de ligando de receptores sigma y aine

Info

Publication number
AR100021A1
AR100021A1 ARP140103392A ARP140103392A AR100021A1 AR 100021 A1 AR100021 A1 AR 100021A1 AR P140103392 A ARP140103392 A AR P140103392A AR P140103392 A ARP140103392 A AR P140103392A AR 100021 A1 AR100021 A1 AR 100021A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
aromatic
nr8r9
heterocyclyl
Prior art date
Application number
ARP140103392A
Other languages
English (en)
Inventor
Cobos-Del-Moral Enrique
Jos - Portillo-Salido Enrique
Zamanillo-Castanedo Daniel
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR100021A1 publication Critical patent/AR100021A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una combinación sinérgica que comprende un ligando sigma, particularmente un ligando sigma de fórmula general (1), y un compuesto AINE, un medicamento que comprende dicha combinación de principios activos, y el uso de dicha combinación de principios activos para la fabricación de un medicamento, particularmente para la profilaxis y/o el tratamiento del dolor. Reivindicación 2: Combinación sinérgica según la reivindicación 1, en la que el al menos un ligando sigma tiene una fórmula general (1) en la que, R¹ se selecciona del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo aromático o no aromático, sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno; R² se selecciona del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo aromático o no aromático, sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno; R³ y R⁴ se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo aromático o no aromático, sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno, o junto con el fenilo forman un sistema de anillo condensado opcionalmente sustituido; R⁵ y R⁶ se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo aromático o no aromático, sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno; o forman juntos, con el átomo de nitrógeno al que están unidos, un grupo heterociclilo aromático o no aromático, sustituido o no sustituido; n se selecciona de 1, 2, 3, 4, 5, 6, 7 y 8; t es 0, 1 ó 2; R⁸ y R⁹ se seleccionan cada uno independientemente de hidrógeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, heterociclilo aromático o no aromático, sustituido o no sustituido, alcoxilo sustituido o no sustituido, ariloxilo sustituido o no sustituido y halógeno; o una sal, isómero, profármaco o solvato farmacéuticamente aceptable del mismo. Reivindicación 9: Combinación sinérgica según una cualquiera de las reivindicaciones anteriores, en la. que el AINE se selecciona del grupo que consiste en paracetamol, ibuprofeno, naproxeno, ketoprofeno, dexketoprofeno, ácido mefenámico, piroxicam, meloxicam, flurbiprofeno, aceclofenaco, acemetacina, alclofenaco, amfenaco, bendazaco, bromfenaco, bumadizona, bufexamaco, diclofenaco, difenpiramida, etodolaco, felbinaco, fentiazaco, indometacina, ketorolaco, lonazolaco, oxametacina, proglumetacina, sulindaco, tolmetina, zomepiraco, celecoxib, cimicoxib, deracoxib, etoricoxib, firocoxib, lumiracoxib, mavacoxib, parecoxib, robenacoxib, rofecoxib, valdecoxib, ampirona, azapropazona, clofezona, kebuzona, metamizol, mofebutazona, nifenazona, oxifenbutazona, fenazona, fenilbutazona, sulfinpirazona, suxibuzona y feprazona. Reivindicación 16: Ligando sigma según una cualquiera de las reivindicaciones 1 a 8, o una sal, isómero, profármaco o solvato farmacéuticamente aceptable del mismo, para su uso en la potenciación sinérgica del efecto analgésico de un AINE cuando dicho AINE se usa en la profilaxis y/o el tratamiento del dolor.
ARP140103392A 2013-09-12 2014-09-11 Combinaciones de ligando de receptores sigma y aine AR100021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382353 2013-09-12

Publications (1)

Publication Number Publication Date
AR100021A1 true AR100021A1 (es) 2016-09-07

Family

ID=49223707

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103392A AR100021A1 (es) 2013-09-12 2014-09-11 Combinaciones de ligando de receptores sigma y aine

Country Status (17)

Country Link
US (1) US20160220574A1 (es)
EP (1) EP3043795A1 (es)
JP (1) JP2016530322A (es)
KR (1) KR20160054547A (es)
CN (1) CN105611925A (es)
AR (1) AR100021A1 (es)
AU (1) AU2014320399A1 (es)
CA (1) CA2922330A1 (es)
IL (1) IL244200A0 (es)
MA (1) MA38957B1 (es)
MX (1) MX2016002892A (es)
PH (1) PH12016500356A1 (es)
RU (1) RU2016113713A (es)
SG (1) SG11201601304XA (es)
TN (1) TN2016000084A1 (es)
TW (1) TW201605433A (es)
WO (1) WO2015036470A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
CN107459510B (zh) * 2016-06-06 2021-06-25 华东师范大学 异恶唑类化合物及其应用
EP3415143A1 (en) * 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexine for the treatment of pain
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP7478761B2 (ja) * 2019-07-03 2024-05-07 エクソンモービル テクノロジー アンド エンジニアリング カンパニー ピラゾリルベンゾエート配位子を含む金属－有機フレームワーク材料、及びその製造方法
CN114728014A (zh) * 2019-11-01 2022-07-08 皮埃蒙特动物健康公司 治疗调配物及其用途
WO2024105225A1 (en) * 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain
CN120860019A (zh) * 2024-04-30 2025-10-31 厦门大学 氯苯唑酸在激活rxr活性中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273329D1 (en) * 1981-06-26 1986-10-23 Upjohn Co Analgesic process and composition
AU2062892A (en) * 1991-08-16 1993-02-18 Mcneil-Ppc, Inc. Potentiation of antitussive effect of dextromethorphan
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
KR101352012B1 (ko) * 2004-08-27 2014-01-15 라보라토리오스 델 드라. 에스테브.에스.에이. 시그마 수용체 저해제
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2292236A1 (en) * 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
AU2013337287B2 (en) * 2012-11-05 2017-03-23 Zafgen, Inc. Methods of treating liver diseases

Also Published As

Publication number Publication date
US20160220574A1 (en) 2016-08-04
IL244200A0 (en) 2016-04-21
AU2014320399A1 (en) 2016-03-10
RU2016113713A3 (es) 2018-06-29
CN105611925A (zh) 2016-05-25
MX2016002892A (es) 2016-06-10
SG11201601304XA (en) 2016-03-30
JP2016530322A (ja) 2016-09-29
PH12016500356A1 (en) 2016-05-16
TW201605433A (zh) 2016-02-16
KR20160054547A (ko) 2016-05-16
EP3043795A1 (en) 2016-07-20
CA2922330A1 (en) 2015-03-19
RU2016113713A (ru) 2017-10-17
WO2015036470A1 (en) 2015-03-19
TN2016000084A1 (en) 2017-07-05
MA38957B1 (fr) 2016-11-30
MA38957A1 (fr) 2016-04-29

Similar Documents

Publication Publication Date Title
AR100021A1 (es) Combinaciones de ligando de receptores sigma y aine
AR101637A1 (es) Combinaciones de gabapentinoides y ligandos de receptores sigma
AR096709A1 (es) Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv)
AR101638A1 (es) Combinaciones de inhibidores de la recaptación de serotonina-norepinefrina (irsn) y ligandos del receptores sigma
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR095858A1 (es) COMBINACIONES DE LIGANDOS DE RECEPTORES ADRENÉRGICOS a-2 Y RECEPTORES SIGMA
AR089550A1 (es) Compuestos quimicos
AR108709A1 (es) Compuestos moduladores de fxr (nr1h4)
AR103252A1 (es) Compuestos de quinazolina
AR096748A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
PE20212253A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
AR090589A1 (es) INHIBIDORES DE b-LACTAMASA ISOXAZOL
AR086636A1 (es) Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
JP2015516427A5 (es)
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
JP2016530322A5 (es)
AR095421A1 (es) Moduladores de p2x7
AR098522A1 (es) Compuesto de triazolo-piridina
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR084173A1 (es) Derivados oxazolil-metileter como agonistas del receptor alx
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)

Legal Events

Date Code Title Description
FB Suspension of granting procedure